Response to Pembrolizumab in a Patient With Xeroderma Pigmentosum and Advanced Squamous Cell Carcinoma-Reference-Cited by-同舟云学术

Response to Pembrolizumab in a Patient With Xeroderma Pigmentosum and Advanced Squamous Cell Carcinoma

Published:2019-12 Issue:3 Volume: Page:1-6
ISSN:2473-4284
Container-title:JCO Precision Oncology
language:en
Short-container-title:JCO Precision Oncology

Author:

Steineck Angela¹,Krumm Niklas²,Sarthy Jay F.¹³,Pritchard Colin C.²,Chapman Teresa²,Stacey Andrew W.²,Vitanza Nicholas A.¹³,Cole Bonnie¹⁴

Affiliation:

1. Seattle Children’s Hospital, Seattle, WA

2. University of Washington, Seattle, WA

3. Fred Hutchinson Cancer Research Center, Seattle, WA

4. University of Washington School of Medicine, Seattle, WA

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/PO.19.00028

Reference27 articles.

1. Kraemer KH, DiGiovanna JJ: Xeroderma pigmentosum, in Adam MP, Ardinger HH, Pagon RA, et al (eds): GeneReviews. Seattle, WA, University of Washington, 2003

2. Cancer and neurologic degeneration in xeroderma pigmentosum: long term follow-up characterises the role of DNA repair

3. Systemic Therapy in Advanced Cutaneous Squamous Cell Carcinoma (CSCC)

4. Phase II Study of Cetuximab As First-Line Single-Drug Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin

5. Rapid response of metastatic cutaneous squamous cell carcinoma to pembrolizumab in a patient with xeroderma pigmentosum: Case report and review of the literature

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Retrospective study of efficacy and adverse events of immune checkpoint inhibitors in 22 xeroderma pigmentosum patients with metastatic or unresectable cancers;Frontiers in Oncology;2023-10-25

2. Homozygous CRISPR/Cas9 Knockout Generated a Novel Functionally Active Exon 1 Skipping XPA Variant in Melanoma Cells;International Journal of Molecular Sciences;2022-10-01

3. Efficacy of pembrolizumab in a patient with xeroderma pigmentosum variant and advanced cutaneous squamous-cell carcinoma;Acta Oncologica;2022-08-11

4. Recurrent squamous cell carcinoma and a novel mutation in a patient with xeroderma pigmentosum: a case report;Journal of Medical Case Reports;2022-07-28

5. Xeroderma pigmentosum: an updated review;DRUGS CONTEXT;2022